Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?

Neurology

Volumn 80, Issue 6, 2013, Pages 583-589

  Scully, Michele A ^a   Cwik, Valerie A ^b   Marshall, Bruce C ^c   Ciafaloni, Emma ^a   Wolff, Jodi M ^b   Getchius, Thomas S ^d   Griggs, Robert C ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Muscular Dystrophy Association   (United States)

^c CYSTIC FIBROSIS FOUNDATION   (United States)

^d AMERICAN ACADEMY OF NEUROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

CONSENSUS; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DUCHENNE MUSCULAR DYSTROPHY; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; LONGEVITY; MOLECULAR DIAGNOSIS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT CODING; PATIENT INFORMATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REGISTER; REVIEW;

HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES; RESEARCH DESIGN;

EID: 84873675018     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318282334e     Document Type: Review

References (35)

1. Gawande A. The bell curve. In: Better: A Surgeon's Notes on Performance. New York: Metropolitan Books; 2007:201-230.
2. Center for Disease Control and Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years: four states, 2007. MMWR Morb Mortal Wkly Rep 2009;58:1119-1122.
3. Fenichel GM, Florence JM, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-1877.
4. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9;77-93.
5. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-189.
6. Aymé S, Rodwell C. 2011 Report on the state of the art of rare disease activities in Europe of the European Union committee of experts on rare diseases: part 1: overview of rare disease activities in Europe and key developments in 2010, July 2011. Available at: http://www.eucerd.eu/upload/file/ Reports/2011ReportStateofArtRDActivities.pdf. Accessed February 7, 2012.
7. Matthews DJ, James KA, Miller LA, et al. Use of cortico-steroids in a population based cohort of boys with Duchenne and Becker muscular dystrophy. J Child Neu-rol 2010;25:1319-1324.
8. Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet 2011;377:1057-1059.
9. Hilbert JE, Kissel JT, Luebbe EA, et al. If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials 2012;33:302-311.
10. Schechter MS, Gutierrez HH. Improving the quality of care for patients with cystic fibrosis. Curr Opin Pediatr 2010;22:296-301.
11. Schechter MS, Margolis P. Improving subspecialty healthcare: lessons from cystic fibrosis. J Pediatr 2005;147:295-301.
12. Quon BS, Goss C. A story of success: continuous quality improvement in cystic fibrosis care in the USA. Thorax 2011;66:1106-1108.
13. Schechter MS. Patient registry analyses: seize the data, but caveat lector. J Pediatr 2008;153:733-755.
14. Cystic Fibrosis Foundation Patent Registry. Annual data report 2010. Available at: http://www.cff.org/UploadedFiles/LivingWithCF/CareCenterNetwork/ PatientRegistry/2010-Patient-Registry-Report.pdf. Accessed February 7, 2012.
15. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;1:CD003725.
16. Moxley RT III, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13-20.
17. Robinson KA, Saldanha IJ, Mckoy NA. Identification of research gaps from evidence-based guidelines: a pilot study in cystic fibrosis. Int J Technol Asses 2011;27:247-252.
18. Cystic Fibrosis Care Guidelines. Available at: http://www.cff.org/ treatments/CFCareGuidelines/. Accessed February 7, 2012.
19. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health related qual-ity-of-life measure for cystic fibrosis. Chest 2005;128:2347-2354.
20. Action Guide for Accelerating Improvement in Cystic Fibrosis Care. Available at: http://www.clinicalmicrosystem.org/assets/-materials/workbooks/ cystic-fibrosis-action-guide.pdf. Accessed February 7, 2012.
21. Cystic Fibrosis Foundation. 2010 annual report. Available at: http://www.cff.org/UploadedFiles/aboutCFFoundation/AnnualReport/ 2010-Annual-Report.pdf. Accessed February 7, 2012.
22. Eagle M, Bourke J, Bullock R, et al. Managing Duchenne muscular dystrophy: the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007;17:470-475.
23. Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12:926-929.
24. Mathews KD, Cunniff C, Kantamneni JR, et al. Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): case definitions in surveillance for childhood-onset Duchenne/Becker muscular dystrophy. J Child Neurol 2010;25:1089-1102.
25. Miller LA, Romitti PA, Cunniff C, et al. The Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology: birth defects research (part A). Clin Mol Technol 2006;76:793-797.
26. Bushby K, Lynn S, Straub V. Collaborating to bring new therapies to the patient: the TREAT-NMD model. Acta Myo 2009;28:12-15.
27. Charter for TREAT-NMD patient database/registry. Available at: http://www.treat-nmd.eu/downloads/file/registries-toolkit/charter-treat-nmd- global-database- approved.pdf. Accessed February 7, 2012.
28. Abbs S, Flanigan K, Tuffery-Giraud S. Mutation Entries in DMD Databases: A Handbook for National Curators. Available at: http://www.treat-nmd.eu/ downloads/file/registries-toolkit/handbook-on-dmd-genetics-jan2009.pdf. Accessed February 7, 2012.
29. CARE-NMD. Available at: http://en.care-nmd.eu/. Accessed February 7, 2012.
30. DuchenneConnect. Available at: https://www.duchenneconnect. org/. Accessed February 7, 2012.
31. Rangel V, Martin AS, Peay HL. DuchenneConnect registry report [Internet]. Version 17. PLoS currents: Muscular Dystrophy. Available at: http://knol.google.com/k/vanessa-rangel/duchenneconnect-registry-report/ 3c8kwqirmpdbh/3. Accessed March 30, 2012.
32. Muscular Dystrophy Association. Available at: http://www.mdausa.org/. Accessed March 30, 2012.
33. Muscular Dystrophy Association Clinical Conference Information. Available at: http://www.mdausa.org/research/national-conferences/2012-clinical- conference/information. htm. Accessed on March 30, 2012.
34. Kenneson A, Vatave A, Finkel R. Widening gap in age at muscular dystrophy-associated death between blacks and whites, 1986-2005. Neurology 2010;75: 982-989.
35. Holtzer C, Meaney FJ, Andrews J, et al. Disparities in the diagnostic process of Duchenne and Becker muscular dystrophy. Genet Med 2011;13:942-947.